Axovant founder and CEO Vivek Ramaswamy has stepped back from the top job, passing the reins to David Hung as the company nears a Phase 3 data readout for its lead Alzheimer's drug candidate.
Pfizer would be acquiring Xtandi, a blockbuster treatment for prostate cancer that is expected to generate annual sales of $1.33 billion by 2020, according to Bloomberg.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Plus, Bristol-Myers Squibb acquires Comorant Pharmaceuticals, Google's DeepMind gets access to eye scans at British hospital and a court rules that biosimilar makers must notify patent-holders six months before launching competitive products.
Also, one group wants to tap videogamers' expertise to develop a better tuberculosis test and MVM Life Science Partners has closed its fourth fund at $233 million.
Also, Color Genomics expands its genetic test portfolio and Apple rolls out first clinical apps developed with CareKit.
BioMarin Pharmaceutials is selling the global license for its PARP inhibitor talazoparibin to Medivation in a $570 million deal. Hatteras Venture Partners has raised $90 million as part of its first close for its fifth venture fund.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
LONDON (Reuters) - Britain's healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service. The draft guidance is conditional on Xtandi being provided at an undiscl...